28 July 2021 - Six month priority review granted for oteseconazole with PDUFA target action date set for 27 January 2022.
Mycovia today announced the U.S. FDA has accepted for review its new drug application for oteseconazole, an oral anti-fungal product for the treatment of recurrent vulvovaginal candidiasis.